Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.13
ALR's Cash to Debt is ranked lower than
92% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.75 vs. ALR: 0.13 )
Ranked among companies with meaningful Cash to Debt only.
ALR' s 10-Year Cash to Debt Range
Min: 0.08  Med: 0.14 Max: N/A
Current: 0.13
Equity to Asset 0.34
ALR's Equity to Asset is ranked lower than
81% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. ALR: 0.34 )
Ranked among companies with meaningful Equity to Asset only.
ALR' s 10-Year Equity to Asset Range
Min: -0.49  Med: 0.38 Max: 0.77
Current: 0.34
-0.49
0.77
Interest Coverage 0.45
ALR's Interest Coverage is ranked lower than
99% of the 95 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1009.34 vs. ALR: 0.45 )
Ranked among companies with meaningful Interest Coverage only.
ALR' s 10-Year Interest Coverage Range
Min: 0.04  Med: 0.48 Max: 3.6
Current: 0.45
0.04
3.6
F-Score: 4
Z-Score: 0.90
M-Score: -2.44
WACC vs ROIC
8.27%
3.90%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 3.51
ALR's Operating margin (%) is ranked higher than
56% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.26 vs. ALR: 3.51 )
Ranked among companies with meaningful Operating margin (%) only.
ALR' s 10-Year Operating margin (%) Range
Min: -92.15  Med: -1.05 Max: 13.42
Current: 3.51
-92.15
13.42
Net-margin (%) 9.09
ALR's Net-margin (%) is ranked higher than
81% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.79 vs. ALR: 9.09 )
Ranked among companies with meaningful Net-margin (%) only.
ALR' s 10-Year Net-margin (%) Range
Min: -149.74  Med: -5.08 Max: 6.61
Current: 9.09
-149.74
6.61
ROE (%) 10.15
ALR's ROE (%) is ranked higher than
77% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.52 vs. ALR: 10.15 )
Ranked among companies with meaningful ROE (%) only.
ALR' s 10-Year ROE (%) Range
Min: -555.34  Med: -5.74 Max: 10.39
Current: 10.15
-555.34
10.39
ROA (%) 3.34
ALR's ROA (%) is ranked higher than
69% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.89 vs. ALR: 3.34 )
Ranked among companies with meaningful ROA (%) only.
ALR' s 10-Year ROA (%) Range
Min: -104.38  Med: -2.83 Max: 3.56
Current: 3.34
-104.38
3.56
ROC (Joel Greenblatt) (%) 7.36
ALR's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.36 vs. ALR: 7.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ALR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -445.57  Med: 7.55 Max: 63.01
Current: 7.36
-445.57
63.01
Revenue Growth (3Y)(%) 2.80
ALR's Revenue Growth (3Y)(%) is ranked lower than
61% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.10 vs. ALR: 2.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ALR' s 10-Year Revenue Growth (3Y)(%) Range
Min: -8.6  Med: 13.30 Max: 73
Current: 2.8
-8.6
73
EBITDA Growth (3Y)(%) -0.60
ALR's EBITDA Growth (3Y)(%) is ranked lower than
55% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. ALR: -0.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ALR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -39.4  Med: 7.95 Max: 103.3
Current: -0.6
-39.4
103.3
EPS Growth (3Y)(%) 14.60
ALR's EPS Growth (3Y)(%) is ranked higher than
75% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. ALR: 14.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ALR' s 10-Year EPS Growth (3Y)(%) Range
Min: -57.6  Med: -9.30 Max: 75.3
Current: 14.6
-57.6
75.3
» ALR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

ALR Guru Trades in Q3 2014

Steven Cohen 1,994,100 sh (New)
Jim Simons 162,900 sh (+117.42%)
Diamond Hill Capital 2,239,478 sh (+110.04%)
Mario Gabelli 263,770 sh (+8.62%)
John Keeley 1,342,615 sh (+0.52%)
Pioneer Investments 541,795 sh (unchged)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Private Capital 908,453 sh (-1.36%)
Manning & Napier Advisors, Inc 3,300,883 sh (-25.51%)
Chuck Royce 268,200 sh (-60.94%)
» More
Q4 2014

ALR Guru Trades in Q4 2014

Joel Greenblatt 382,075 sh (New)
Jim Simons 390,124 sh (+139.49%)
Diamond Hill Capital 2,669,006 sh (+19.18%)
John Keeley 1,349,075 sh (+0.48%)
Private Capital 902,223 sh (-0.69%)
Chuck Royce 222,700 sh (-16.96%)
Mario Gabelli 203,100 sh (-23.00%)
Steven Cohen 1,529,167 sh (-23.32%)
Manning & Napier Advisors, Inc 1,313,248 sh (-60.22%)
Manning & Napier Advisors, Inc 1,313,248 sh (-60.22%)
Pioneer Investments 166,304 sh (-69.30%)
» More
Q1 2015

ALR Guru Trades in Q1 2015

Jim Simons 1,266,124 sh (+224.54%)
Mario Gabelli 208,150 sh (+2.49%)
Private Capital 911,238 sh (+1.00%)
Pioneer Investments Sold Out
Chuck Royce Sold Out
Joel Greenblatt Sold Out
Diamond Hill Capital 2,544,479 sh (-4.67%)
John Keeley 1,240,717 sh (-8.03%)
Manning & Napier Advisors, Inc 838,826 sh (-36.13%)
Steven Cohen 49,000 sh (-96.80%)
» More
Q2 2015

ALR Guru Trades in Q2 2015

Manning & Napier Advisors, Inc 682,226 sh (-18.67%)
» More
» Details

Insider Trades

Latest Guru Trades with ALR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Alere Inc

SymbolPriceYieldDescription
ALRPRB338.353.55

Guru Investment Theses on Alere Inc

Diamond Hill Capital Comments on Alere Inc - Mar 17, 2015

Diagnostic systems provider Alere, Inc. (ALR) declined after installing a new CEO during the quarter, while weathering an unsolicited attempt by the previous CEO to take the company private. Subsequently, the company announced that it would sell its Health Management business in a first sign of the implementation of a new agenda focused on asset sales and debt paydown.

From Diamond Hill Capital (Trades, Portfolio)’s Select Fund Q4 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Mario Gabelli Comments on Alere Inc - Nov 21, 2014

Alere Inc. (0.2% of net assets as of September 30, 2014) (ALR - $38.78 - NYSE) is the largest manufacturer of rapid, point-of-care diagnostics in the world. The company has underperformed for the past year, weighed down by manufacturing problems and a heavy debt load from questionable past acquisitions. An activist investor has been publicly pushing the company to improve operations and, after being slow to respond initially, Alere’s Board of Directors forced the company’s founder and CEO to resign on July 1. However, he has now partnered with private equity partners and is seeking to take the company private with an initial bid of $46 per share. Whatever the final outcome is, we believe positive change is in the air for Alere.

From Mario Gabelli (Trades, Portfolio)’s Asset Fund Q3 2014 Commentary.

Check out Mario Gabelli latest stock trades

Diamond Hill Capital Comments on Alere Inc - Oct 17, 2014

We initiated a new position in diagnostic systems provider Alere, Inc (ALR). We believe the company has the potential to grow intrinsic value by focusing on cost savings, asset disposals, and debt pay-down. All three of these initiatives would represent avenues to unmask the true long-term earnings power of the company and its core point-of-care diagnostics business. We forecast earnings well above the current consensus estimates.

From Diamond Hill Capital (Trades, Portfolio)'s Select Fund Third Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about Alere Inc

Diamond Hill Capital Comments on Alere Inc
Diagnostic systems provider Alere, Inc. (ALR) declined after installing a new CEO during the quarter, while weathering an unsolicited attempt by the previous CEO to take the company private. Subsequently, the company announced that it would sell its Health Management business in a first sign of the implementation of a new agenda focused on asset sales and debt paydown. Read more...
Mario Gabelli Comments on Alere Inc
Alere Inc. (0.2% of net assets as of September 30, 2014) (ALR - $38.78 - NYSE) is the largest manufacturer of rapid, point-of-care diagnostics in the world. The company has underperformed for the past year, weighed down by manufacturing problems and a heavy debt load from questionable past acquisitions. An activist investor has been publicly pushing the company to improve operations and, after being slow to respond initially, Alere’s Board of Directors forced the company’s founder and CEO to resign on July 1. However, he has now partnered with private equity partners and is seeking to take the company private with an initial bid of $46 per share. Whatever the final outcome is, we believe positive change is in the air for Alere. Read more...
Diamond Hill Capital Comments on Alere Inc
We initiated a new position in diagnostic systems provider Alere, Inc (ALR). We believe the company has the potential to grow intrinsic value by focusing on cost savings, asset disposals, and debt pay-down. All three of these initiatives would represent avenues to unmask the true long-term earnings power of the company and its core point-of-care diagnostics business. We forecast earnings well above the current consensus estimates. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 27.52
ALR's P/E(ttm) is ranked higher than
56% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.10 vs. ALR: 27.52 )
Ranked among companies with meaningful P/E(ttm) only.
ALR' s 10-Year P/E(ttm) Range
Min: 26.09  Med: 179.26 Max: 3605
Current: 27.52
26.09
3605
Forward P/E 18.98
ALR's Forward P/E is ranked higher than
53% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.00 vs. ALR: 18.98 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 2.79
ALR's P/B is ranked higher than
57% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.58 vs. ALR: 2.79 )
Ranked among companies with meaningful P/B only.
ALR' s 10-Year P/B Range
Min: 0.42  Med: 1.58 Max: 3.12
Current: 2.79
0.42
3.12
P/S 1.58
ALR's P/S is ranked higher than
72% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.95 vs. ALR: 1.58 )
Ranked among companies with meaningful P/S only.
ALR' s 10-Year P/S Range
Min: 0.52  Med: 1.38 Max: 4.12
Current: 1.58
0.52
4.12
PFCF 70.40
ALR's PFCF is ranked lower than
79% of the 63 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 28.48 vs. ALR: 70.40 )
Ranked among companies with meaningful PFCF only.
ALR' s 10-Year PFCF Range
Min: 8.97  Med: 19.82 Max: 135.97
Current: 70.4
8.97
135.97
POCF 25.99
ALR's POCF is ranked lower than
61% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.03 vs. ALR: 25.99 )
Ranked among companies with meaningful POCF only.
ALR' s 10-Year POCF Range
Min: 4.63  Med: 11.87 Max: 132.61
Current: 25.99
4.63
132.61
EV-to-EBIT 95.42
ALR's EV-to-EBIT is ranked lower than
93% of the 89 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.73 vs. ALR: 95.42 )
Ranked among companies with meaningful EV-to-EBIT only.
ALR' s 10-Year EV-to-EBIT Range
Min: -884.5  Med: 40.20 Max: 2833.4
Current: 95.42
-884.5
2833.4
Current Ratio 2.18
ALR's Current Ratio is ranked lower than
58% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. ALR: 2.18 )
Ranked among companies with meaningful Current Ratio only.
ALR' s 10-Year Current Ratio Range
Min: 0.7  Med: 1.75 Max: 3.42
Current: 2.18
0.7
3.42
Quick Ratio 1.61
ALR's Quick Ratio is ranked lower than
65% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.31 vs. ALR: 1.61 )
Ranked among companies with meaningful Quick Ratio only.
ALR' s 10-Year Quick Ratio Range
Min: 0.46  Med: 1.21 Max: 2.89
Current: 1.61
0.46
2.89
Days Inventory 101.97
ALR's Days Inventory is ranked lower than
63% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.75 vs. ALR: 101.97 )
Ranked among companies with meaningful Days Inventory only.
ALR' s 10-Year Days Inventory Range
Min: 38.42  Med: 85.69 Max: 130.6
Current: 101.97
38.42
130.6
Days Sales Outstanding 69.44
ALR's Days Sales Outstanding is ranked lower than
55% of the 157 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.45 vs. ALR: 69.44 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALR' s 10-Year Days Sales Outstanding Range
Min: 51.97  Med: 66.69 Max: 166.61
Current: 69.44
51.97
166.61

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.34
ALR's Price/Projected FCF is ranked higher than
73% of the 67 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.97 vs. ALR: 1.34 )
Ranked among companies with meaningful Price/Projected FCF only.
ALR' s 10-Year Price/Projected FCF Range
Min: 0.43  Med: 1.04 Max: 6.47
Current: 1.34
0.43
6.47
Price/Median PS Value 1.18
ALR's Price/Median PS Value is ranked lower than
62% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.12 vs. ALR: 1.18 )
Ranked among companies with meaningful Price/Median PS Value only.
ALR' s 10-Year Price/Median PS Value Range
Min: 0.37  Med: 0.95 Max: 2.96
Current: 1.18
0.37
2.96
Earnings Yield (Greenblatt) (%) 1.01
ALR's Earnings Yield (Greenblatt) (%) is ranked higher than
54% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. ALR: 1.01 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ALR' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.3  Med: 1.70 Max: 3
Current: 1.01
0.3
3

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, DGX, LIFE, ENZ, IDXX » details
Traded in other countries:IM5.Germany,
Alere Inc formerly known as Inverness Medical Innovations, Inc. is a Delaware corporation incorporated on August 25,1992, which was formed to acquire the women's health, nutritional supplements and professional diagnostics businesses of its predecessor, Inverness Medical Technology, Inc., through a split-off and merger transaction, which occurred in November 2001. The Company enables individuals to take control of their health at home, under the supervision of their healthcare providers, by connecting innovative diagnostics in the hands of patients to their healthcare providers. The Company is a provider of point-of-care diagnostics and services; and has developed a strong commercial presence in infectious disease, toxicology, cardiology and diabetes. Its products and services help healthcare practitioners make earlier, more effective treatment decisions and improve outcomes for individuals living with chronic disease. Its portfolio also includes a broad array of health information solutions that increase access to critical health data, provide clinical decision support and facilitate more comprehensive performance reporting and analysis. The Company's operating segments are professional diagnostics, health information solutions and consumer diagnostics. Professional Diagnostics solutions allow patients and their healthcare providers to work together to better manage patients' chronic conditions over the continuum of care, from the hospital to home. It is generally designed to assist medical professionals in both preventative and interventional medicine, and include testing and monitoring performed in hospitals, laboratories and doctors' offices and, increasingly, patient self-testing, which defined as testing or monitoring performed at home under the supervision of a medical professional. Its products provide for qualitative or quantitative analysis of patient samples for evidence of a specific medical condition, disease state or toxicological state or to measure response to therapy. In professional diagnostics, Company focus on point-of-care, rapid diagnostic testing and the developing patient self-testing and patient self-management markets where it can directly and immediately improve patient health outcomes. Its products include point-of-care and laboratory tests within the following areas; Infectious Disease, Toxicology, Cardiology, Diabetes, Oncology, Women's Health and Connected Device Technologies. Its health information solutions are designed to provide physicians with actionable data that allows them to make more effective decisions in real time, deliver quality care, and put the individuals they treat on a pathway to better health. It offers a variety of software-based analytics, clinical decision-support tools, and accountable care programs that enable healthcare providers to initiate earlier interventions, personalize treatment plans, lower costs by reducing hospital readmissions, and measure improvements in outcome
» More Articles for ALR

Headlines

Articles On GuruFocus.com
Alder Shareholders Approve Acquisition of Alder Resources Ltd. by Midlands Minerals Corporation Jul 08 2015 
The Transformation in Alere May 22 2015 
Diamond Hill Capital Comments on Alere Inc Mar 17 2015 
Corsair Capital's Analysis of Alere Mar 06 2015 
DENTSPLY´s Growth Opportunities Dec 16 2014 
Hologic Produces the First FDA-Approved 3D Mammography Platform Nov 26 2014 
Mario Gabelli Comments on Alere Inc Nov 21 2014 
Mario Gabelli’s Asset Fund Q3 2014 Commentary Nov 21 2014 
Cohen Has Busy Third Quarter Nov 19 2014 
Alder Reports Encouraging Copper and Gold Metallurgical Recovery Results for the Stockpiles and Tail Nov 05 2014 

More From Other Websites
Altera FPGAs Power New RICOH SP 3600DN Printer Series Jul 30 2015
Altera Receives Favorable Opinion on Cost-Sharing Litigation Jul 29 2015
Alere to Report Second Quarter 2015 Financial Results on August 4, 2015 Jul 28 2015
Alere to Report Second Quarter 2015 Financial Results on August 4, 2015 Jul 28 2015
Altera Announces Second Quarter Results Jul 23 2015
Dr. Geoffrey S. Ginsburg Joins Alere Board Jul 23 2015
ALERE INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jul 23 2015
Dr. Geoffrey S. Ginsburg Joins Alere Board Jul 23 2015
Altera “Aces It” at the Annual EE Times/EDN ACE Awards Jul 22 2015
Notification of transactions on the Bank’s shares Jul 22 2015
Altera Showcases the Capabilities of Single-Chip Configurable Processors in Latest MAX 10 FPGA Kit Jul 21 2015
Notification of transactions on the Bank’s shares Jul 20 2015
CLIA Waiver for Alere i Strep A Test, Divestment Plans on Track - Analyst Blog Jul 17 2015
Alere sells one business for $164M, buys another for $60M Jul 16 2015
Alere Continues to Execute on Core Business Strategy through Agreement to Sell BBI Group and... Jul 16 2015
Alere Receives FDA CLIA Waiver for Alere™ i Strep A Rapid Molecular Test Jul 16 2015
Alere Receives FDA CLIA Waiver for Alere™ i Strep A Rapid Molecular Test Jul 16 2015
Alere Continues to Execute on Core Business Strategy through Agreement to Sell BBI Group and... Jul 16 2015
Notification of transactions on the Bank’s shares Jul 15 2015
Current report drafted according to the provisions of the article 226 of the Law no. 297/2004 Jul 13 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK